Antimicrobial Resistance Diagnostics Market Size

Antimicrobial Resistance Diagnostics Market Size

The global antimicrobial resistance diagnostics market was valued at USD 4.4 billion in 2023 and is estimated to grow at a CAGR of over 6.3% from 2024 to 2032. The market is experiencing significant growth due to the increasing prevalence of antibiotic-resistant infections, rising demand for personalized medicine, and surging advancements in diagnostic technology.

To get key market trends

  Download Free Sample

For example, according to the CDC, at least 2.8 million people in the U.S. are infected with antibiotic-resistant bacteria annually, leading to over 35,000 deaths. This escalating threat highlights the urgent need for accurate diagnostics to manage infections effectively, further driving market growth.

Moreover, advancements and innovations in molecular diagnostics, immunoassays, and next-generation sequencing (NGS) have improved the accuracy and speed of resistance detection. For instance, molecular diagnostics are particularly favored for their rapid results and high precision, which contributes to their dominance in the market. Furthermore, governments and health organizations increasingly recognize antimicrobial resistance (AMR) as a critical public health issue, leading to funding and initiatives to enhance diagnostic capabilities. In the U.S., for example, the National Action Plan for Combating Antibiotic-Resistant Bacteria emphasizes the importance of rapid diagnostic tests.

Antimicrobial resistance (AMR) threatens the effective prevention and treatment of a growing range of infections caused by bacteria, parasites, viruses, and fungi. Rapid diagnostic tests that identify drug-resistant bacteria, determine antimicrobial susceptibility, and distinguish viral from bacterial infections can guide effective treatment strategies. Additionally, rapid diagnostic tests can support epidemiological surveillance, as emerging resistant infectious agents and their transmission can be monitored.